BRIEF—Takeda considers deal with leon-nanodrugs to reformulate products

Germany’s leon-nanodrugs says that Takeda Pharmaceutical is undertaking a formal feasibility assessment of its ‘MicroJet Reactor’ nano-technology, with a view towards developing “an innovative formulation of one of their current pipeline products.”

leon says that positive results from this feasibility study could potentially result in a long-term collaboration between the companies, and additional compounds may also be considered.

The firm’s MJR technology offers reformulation options that can “lead to a superior profile for the API by increasing bioavailability, reducing inter patient variability, improving onset of action.”